As President and CEO, Donald Olds is leading the entire NEOMED initiative. He is in charge of the strategic planning, the corporate development, and the integration of all components of the NEOMED Institute in the local, national, and international R&D communities.
Prior to be named President and CEO of the NEOMED Institute in January 2017, Donald Olds was Chief Operating Officer of Telesta Therapeutics Inc. a publicly-listed biotechnology company (TSX: TST). At Telesta, he was responsible for finance and investor relations, manufacturing operations, business development, human resources and strategy. Over the course of his three-year tenure, he led a successful U.S. financing to fund the U.S. commercial launch of Telesta’s bladder cancer therapeutic and negotiated a significant ex-U.S. License for the same asset. In October 2016, he led the process that led to the successful sale of Telesta Therapeutics to a larger public biotechnology company.
Prior to Telesta Therapeutics, he was President and CEO of Presagia Corp., a private Montreal-based software development company focused on developing innovative solutions for workforce management for large US-based organizations. In this role, he led several successful private financings and helped build Presagia’s reputation for delivering quality decision support software solutions to complex organizations.
Before joining Presagia, he worked for almost 9 years as Chief Financial Officer and Chief Operating Officer of Aegera Therapeutics, where he was responsible for clinical operations, business development, finance, and Mergers and Acquisitions. During his tenure, Aegera raised over $100 Million in growth capital, initiated 5 clinical development programs, acquired a private oncology company, and executed multiple licensing transactions, one of which was recognized as the largest preclinical licensing transaction ever closed in Canada.
Prior to Aegera Therapeutics, Mr. Olds was Chief Financial Officer of Mediatrix Telecom where he was responsible for operations, finance and manufacturing and led the technology investment banking practice of TD Securities in Quebec.
Mr. Olds is currently Chairman of Oxfam Quebec and Director of Presagia Corp. and has extensive past corporate governance experience serving on the boards of private and public for-profit and not-for-profit organizations. He holds an MBA (Finance & Strategy) and M.Sc. (Renewable Resources) from McGill University. He has travelled extensively and worked in Senegal, West Africa for two years as a foreign expert on a Canadian development project. He lives in Montreal with his family.
Philippe Walker is in charge of a team of seasoned project directors who jointly support the advancement of the NEOMED portfolio. He takes part in the evaluation of projects and ensures that efficient strategies are established and implemented to deliver human proofs of concept.
Until June 2012, Philippe was Vice-President and Head of the AstraZeneca R&D Montreal (AZRDM) research centre that delivered multiple drug candidates to the AZ portfolio. Philippe was also a member of AstraZeneca’s Global iMed leadership team for NeuroScience. He was recruited in 1994 by Astra to help select a North American location for the company’s analgesia drug discovery activities and he was instrumental in establishing the Astra Research Centre in Montreal. Initially, he led the company’s molecular biology activities. In 1999, shortly after the company inaugurated its new laboratories in Saint-Laurent, Philippe was appointed to head the company site and research activities in Montreal. From 1988 to 1994, Dr. Walker headed the molecular biology laboratory of the Division of Hypertension (Prof. H. R. Brunner) of the Faculty of Medicine of Lausanne Switzerland, where he was Assistant Professor. His work focused on the functional characterization of the receptor for Neuropeptide Y and was sponsored by a S.T.A.R.T. career development award fellowship from the Swiss National Science Foundation and by a grant from the CIBA Corporation. From 1986 to 1988, Philippe worked with Dr. Ronald Reeder at the Fred Hutchinson Cancer Centre in Seattle on the isolation and characterization of proteins interacting with gene promoters and on the control of gene transcription.
Philippe studied at the University of Fribourg and Lausanne in Switzerland where he obtained his PhD in Science in 1986. His research in the laboratory of Prof. Walter Wahli focused on the study of estrogen-regulated gene expression. His work resulted in the discovery of the ERE (estrogen response elements).
Pierre-Yves manages the financial and administrative activities of the NEOMED Institute. In particular, he is responsible for developing, implementing, and maintaining systems such as accounting, cash flow, and budgeting, as well as the financial analysis and management reporting. He works collaboratively with management on different projects with regards to the development and implementation of the strategic plan of the NEOMED Institute, to which he brings the financial perspective. Pierre-Yves also supervises the information technology operations, as well as facility management.
Pierre-Yves has extensive professional experience, mostly in the biotech/pharmaceutical industry as CFO. Before joining the NEOMED Institute, he offered financial consulting services, such as in-house CFO and financial structuring. Over the years, he was exposed to issues related to publicly listed companies as CFO, and as Director and Chairman of audit committees. He also raised financing in the private sector (non-dilutive and dilutive) with venture capitalists and individuals. He was previously Investment Portfolio Manager, Life Sciences, at the Fonds de solidarité des travailleurs du Québec (FSTQ).
He remains involved in the development of the CPA profession, representing the OCAQ on the Board of Evaluators (jury for the “UFE”) of the CICA. In addition, he is an author of two reference manuals in financing and treasury management, as well as course instructor for the OCAQ.
He was recently appointed as Chairman of the Board of the Théâtre Denis-Pelletier, a well-known institution with a primary mission to introduce young people to the theater. Pierre-Yves also sits on the Board of Directors at Replicor Inc. In addition to being a CPA, CA, he received a Corporate Finance (CF) qualification from the CICA and has an MBA from the Hautes Études Commerciales of the Université de Montréal.
In his current role, Dan aims to demonstrate the value of NEOMED Institute’s new R&D model by bringing assets to the clinical proof-of-concept stage of maturation. Dan also plays a key role in the review of potential project candidates, where he brings the long-term medical vision and a deep understanding of R&D opportunities and constraints to NEOMED Institute’s search for value creation.
In 2007, Dan founded Kompas Medical Services Inc., a company providing support to biotechs, pharmas, and other institutions including hospitals. During his five years as CEO, Dan had the opportunity to develop his entrepreneurial spirit and flexibility serving a great variety of clients and programs, across a wide range of geographic areas and cultures. The company is still active today with Dan as its owner. The main therapeutic areas in which Kompas’ customers operate are fibrosis, oncology, hypertension, diabetes, COPD, asthma, Alzheimer’s disease, genetics, and infectious diseases.
Prior to this, Dan worked for over 20 years within the top-tier pharmaceutical companies Glaxo and Bristol-Myers Squibb, where he served as an executive in Clinical Research and Medical Affairs. He has been involved in key aspects of clinical development for compounds in various therapeutic areas, including infectious diseases, HIV, hepatitis, influenza, and rheumatoid arthritis, and as such, is very familiar with the clinical research standards of the ICH, FDA, and EMEA. During his 20 years with major pharmaceuticals, he advised on the use of medical communication tools, medical concepts, and effective KOL networks towards the optimization of product properties and the maximization of their market impact. As an executive manager, he was directly involved in the structuring of human resources and processes to deliver, on schedule, high-quality outputs in clinical research and medical affairs.
Dan is a member of the Board of Directors of Thallion Pharmaceuticals Inc. (TSX: TLN), a publicly traded biotechnology company based in Montreal.
Dan is a Medical Doctor with additional training in biostatistics (as part of a Master in Human Biology program) from Paris-Sud University and holds a Master in Marketing and Commercial Development (equivalent to an MBA) from HEC in France.
As Vice President, Business Development, Daniel Böck is primarily responsible for finding, and realizing, strategic partnerships and/or collaborations around the NEOMED Institute’s late-stage programs while also looking for earlier-stage opportunities from either academia or research institutions to ensure continuity in the NEOMED Institute’s pipeline. Additionally, Daniel will be playing a key role publicizing the NEOMED Institute and its “one-of-a-kind” and “unique multidisciplinary” approach in addressing the considerable gap between basic research and the commercialization of new medicines.
Prior to joining the NEOMED Institute team, Daniel held the position of Director, Business Development with GlaxoSmithKline (GSK) in Canada where he sought to identify acquisition, licensing, and/or distribution opportunities for the Canadian market as well as roll out the GSK Canada Innovation Fund intended to strategically invest in, and financially support, innovative research within the Canadian life sciences industry.
During his career, Daniel has also held the position of Vice President, Business Development in a small Montreal-based biotechnology company and so has an appreciation for, and understanding of, both big pharma and small biotech perspectives.
Daniel brings 23 years of industry experience in sales, product management, marketing, venture capital, and business development, having had either regional or worldwide responsibilities in these roles.